Search Results - Stanislas Pol

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Cover Image

    HCV: is mission accomplished? The pros by Stanislas Pol

    Published 2016
    Connect to this object online.
    Book

    Save to List
    Saved in:
  2. 2
    Cover Image

    Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS). by Stanislas Pol, Fayssoil Fouad, Magali Lemaitre, Ingrid Rodriguez, Olivier Lada, Pascaline Rabiega, Elias Benabadji, Françoise Roudot-Thoraval

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:
  3. 3
    Cover Image

    Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort by Tangui Barré, Fabrice Carrat, Clémence Ramier, Hélène Fontaine, Vincent Di Beo, Morgane Bureau, Céline Dorival, Dominique Larrey, Elisabeth Delarocque-Astagneau, Philippe Mathurin, Fabienne Marcellin, Ventzislava Petrov-Sanchez, Carole Cagnot, Patrizia Carrieri, Stanislas Pol, Camelia Protopopescu, the ANRS/AFEF Hepather study group

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:
  4. 4
    Cover Image

    Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial by Fabien Zoulim, Claire Fournier, François Habersetzer, Martin Sprinzl, Stanislas Pol, Carla S Coffin, Vincent Leroy, Mang Ma, Heiner Wedemeyer, Ansgar W Lohse, Robert Thimme, Karine Lugardon, Perrine Martin, Bérangère Bastien, Benoit Sansas, Nathalie Adda, Celine Halluard, Kaïdre Bendjama, Maud Brandely, Geneviève Inchauspé

    Published 2020
    Connect to this object online.
    Book

    Save to List
    Saved in:
  5. 5
    Cover Image

    Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS CO22 Hepather Cohort) by Tangui Barré, Hélène Fontaine, Stanislas Pol, Clémence Ramier, Vincent Di Beo, Camelia Protopopescu, Fabienne Marcellin, Morgane Bureau, Marc Bourlière, Céline Dorival, Ventzislava Petrov-Sanchez, Tarik Asselah, Elisabeth Delarocque-Astagneau, Dominique Larrey, Jean-Charles, Fabrice Carrat, Patrizia Carrieri, on behalf of the ANRS/AFEF Hepather Study Group

    Published 2022
    Connect to this object online.
    Book

    Save to List
    Saved in:
  6. 6
    Cover Image

    P62 High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1-6 patients without cirrhosis by Massimo Puoti, Graham Foster, Stanley Wang, David Mutimer, Edward Gane, Christophe Moreno, Ting Tsung Chang, SamS Lee, Rui Marinho, Jean-Francois DuFour, Stanislas Pol, Christophe Hezode, Stuart C. Gordon, Simone I. Strasser, Paul J. Thuluvath, Ran Liu, Tami Pilot-Matias, Federico Mensa

    Published 2017
    Connect to this object online.
    Book

    Save to List
    Saved in:
  7. 7
    Cover Image

    P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure by Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert W. Reindollar, Stuart C. Gordon, Stephen Pianko, Michael W. Fried, David E. Bernstein, Joel Gallant, Chih-Wei Lin, Yang Lei, Teresa I. Ng, Tami Pilot-Matias, Jens Kort, Federico Mensa

    Published 2017
    Connect to this object online.
    Book

    Save to List
    Saved in:

Search Tools: